Oncolin Therapeutics Lead Cancer Technology is Being Presented Today at the Annual Meeting of The American Association for Cancer Research
The poster presented today, abstract #3359, from the AACR proceedings, volume 49, April 2008, entitled "2-Deoxy-2-fluoro-D-mannose induces type II cell death in gliomas." In this poster data is presented on novel sugar analogs that show positive activity against energy starved tumors, in particular glioma cell lines, and induce cell death for these tumor cells. This data provides additional proof that targeting energetic metabolism of cancer cells using inhibitors of glycolysis is a promising approach to the treatment of tumors that depend on glycolysis for survival. Oncolin retains rights to these compounds and others through an agreement with the University of Texas M.D. Anderson Cancer Center.
"We are very pleased to have further data presented on our lead program for brain cancer treatment at such a prestigious cancer meeting such as this. This data provides further evidence that our approach for a novel treatment for brain cancers is clearly promising," said Dr Donald Picker, President and COO.
Oncolin announces its lead technology has shown to be effective in treating cancer in animal models.
Oncolin Therapeutics Obtains an Exclusive Worldwide Right to Option Patents Covering the Composition and Use of Genistein Analogs for Cancer Treatment
Oncolin has recently announced that is has obtained an exclusive option agreement with the Pharmaceutical Research Institute of Warsaw, Poland which provides the company the right to license the use of Genistein analogs for cancer treatment.
About Oncolin Therapeutics, Inc.
Headquartered in Houston, Texas, Oncolin Therapeutics, Inc. is a publicly traded biopharmaceutical company that engages in the discovery, development and commercialization of novel selective anticancer therapies. Additional information about Oncolin can be found on the web at www.oncolinthera.com.
Safe Harbor Statement
This press release contains statements that may constitute forward-looking statements, including the company's ability to successfully acquire and develop technologies that are and may be acquired. These statements are based on current expectations and assumptions and involve a number of uncertainties and risks that could cause actual results to differ materially from those currently expected. For additional information about Oncolin's future business and financial results, refer to Oncolin's Quarterly Report on Form 10-QSB for the quarter ended December 31, 2007 and Annual Report on Form 10-KSB for the year ended March 31, 2007. Oncolin Therapeutics undertakes no obligation to update any forward-looking statement that may be made from time to time by or on behalf of the company, whether as a result of new information, future events or otherwise.
Oncolin Therapeutics, Inc., Houston
J. Leonard Ivins, 713-621-5208
Posted: April 2008